Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.
The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.
In the final part, we explore the role of people affected by MS in the Octopus trial. Susan Scott, a pharmaceutical publications specialist and Octopus patient representative, shares her involvement in the trial and explains how PPI has benefited Octopus so far.
14
11/8/2023
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.
The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.
In Part 3, MS experts Dawn Lyle and Matthew Justin walk us through the journey that trial participants take when taking part in Octopus, from how to register your interest in the trial, to what to expect on your first visit.
3
11/1/2023
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.
The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.
Part 2 of the series explores our Octopus trial in depth. Professor Jeremy Chataway, lead investigator of Octopus, discusses its novel design, the treatments it will test, and the criteria for people to take part. He also explains the data researchers will collect and analyse to find out if a treatment is working.
1
10/24/2023
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS). Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.
The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.
Part 1 covers the treatment and research landscape of MS and the challenges of treating progressive MS. It features Jeremy Chataway, neurologist at National Hospital for Neurology and Neurosurgery at UCLH and Professor of Neurology at UCL, who is leading the Octopus trial. We also hear from Dawn Lyle, Lead Research MS Nurse, and Matthew Justin, MS Specialist, who are based at the Anne Rowling Regenerative Neurologic Clinic in Edinburgh.
5
10/19/2023
Innovative platform designs present an opportunity to run faster and more efficient clinical trials.
Clinical trials methodology is a research area that looks at how to improve the design, conduct, and analysis of clinical trials. It focuses on developing and implementing new methods to help run trials faster and more efficiently, that will ultimately accelerate the discovery of new treatments.
In this episode, methodologist Matteo Quartagno tells us about a new clinical trial design called MAMS-ROCI. It is a type of multi-arm multi-stage design that compares a range of different treatment durations, doses or frequencies to identify the optimal one.
1
9/20/2023
Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer.
However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side effects.
In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs.
Further information is available on the REFINE study page at www.mrcctu.ac.uk
For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk
For more information and to access the transcript: https://bit.ly/3DgIDE2
1
7/18/2023
Neonatal sepsis is a life-threatening infection that affects up to 3 million babies per year globally.
In an effort to identify better treatments, the NeoSep1 clinical trial evaluates new antibiotic combinations for newborn babies with sepsis. To learn more about the trial, we speak to Adrie Bekker and Cristina Obiero, principal investigators of the trial in South Africa and Kenya, Reenu Thomas, a neonatologist from South Africa, and Francesca Schiavone, the clinical project manager of the NeoSep1 trial in London.
2
6/8/2023
214,000 newborn babies die of sepsis caused by infections that are resistant to antibiotics every year. This is a major problem worldwide, but disproportionally affects low- and middle- income countries.
Reenu Thomas and Adrie Bekker, two neonatologists from South Africa, and Francesca Schiavone, clinical project manager at the MRC CTU at UCL in London, discuss the challenges of treating neonatal sepsis and present the results from an observational study (NeoOBS), which assessed mortality rates of babies with sepsis.
3
5/17/2023